Clinical heterogeneity in Fabry disease: A clinical case

Assel Issabekova 1 * , Olga Mashkunova 2
More Detail
1 Cardiology Department, Scientific Institution of Cardiology and Internal Diseases, Almaty, Kazakhstan
2 Therapeutic Department, National Medical University, Almaty, Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 20, Issue 4, pp. 68-70. https://doi.org/10.23950/jcmk/13486
OPEN ACCESS 627 Views 482 Downloads
Download Full Text (PDF)

ABSTRACT

Fabry disease is an orphan lysosomal storage disease characterized by progressive organ damage. Considering that the disease is rare, the low awareness of doctors about this pathology leads to late diagnosis of the disease and untimely pathogenetic therapy. Clinical case of late (relative to clinical manifestation) diagnosis of the “classical” phenotype of Fabry Disease in a male patient with cardiac and renal damage and typical early presentations such as neuropathic pain, angiokeratomas, hypohidrosis.

CITATION

Issabekova A, Mashkunova O. Clinical heterogeneity in Fabry disease: A clinical case. J CLIN MED KAZ. 2023;20(4):68-70. https://doi.org/10.23950/jcmk/13486

REFERENCES

  • Vedder A. C., Strijland A., vd Bergh Weerman M. A., Florquin S., Aerts J. M., Hollak C. E. Manifestations of Fabry disease in placental tissue. J. Inherit. Metab. Dis. 2006; 29: 106–111. https://doi.org/10.1007/s10545-006-0196-0
  • Redonnet-Vernhet I., Ploos van Amstel J.K.,Jansen R.P., R A Wevers, R Salvayre, T Levade. Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alphagalactosidase A gene. J Med Genet. 1996; 33:682–8. https://doi.org/10.1136/jmg.33.8.682
  • Spada M., Pagliardini S., Yasuda M., Tukel T., Thiagarajan G., Sakuraba H., Ponzone A., Desnick R. J. High incidence of later-onset fabry disease revealed by newborn screening. Am. J. Hum. Genet. 2006; 79: 31–40. https://doi.org/10.1086/504601
  • Hoffmann B., Beck M., Sunder-Plassmann G., Borsini W., Ricci R., Mehta A. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy — a retrospective analysis from the Fabry Outcome Survey. Clin J. Pain. 2007; 23. https://doi.org/10.1097/AJP.0b013e318074c986
  • Arends M, Wanner C, Hughes D, et al. Characterization of classical and nonclassicalFabry disease: a multicenterstudy. J Am SocNephrol. 2017; 28:16-31.
  • Michaud M, Mauhin W, Belmatoug N, et al. When and how to diagnose Fabry disease in clinical practice. Am J Med Sci. 2020; 3:1-9.
  • А.Ortiz, B.Cianciaruso, M. Cizmarik, Dominique P. Germain, R. Mignani, João Paulo Oliveira, J. Villalobos, B. Vujkovac, S. Waldek, Ch. Wanner. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant. 2010; 25:769-775. https://doi.org/10.1093/ndt/gfp554
  • Reisin R, Perrin A, García-Pavía P. Time delays in the diagnosis and treatment of Fabry disease. Int J ClinPract. 2017; 71(1):e12914. https://doi.org/10.1111/ijcp.12914
  • Novikov P.V., Asanov A. Yu., Kopishinskaya S.V. Federal clinical guidelines for the diagnosis and treatment of Fabry disease. M.; 2013 (in Russian).
  • Úçeyler N., Ganendiran S., Kramer D., Sommer C. Characterization of pain in Fabry disease. Clin J Pain. 2014; 30:915–920. https://doi.org/10.1097/AJP.0000000000000041
  • Laaksonen S.M., Roytt S.K., Kantola I. Et al. Neuropathic symptoms and findings in women with Fabry disease. ClinNeurophysiol. 2008; 119:1365–1372. https://doi.org/10.1016/j.clinph.2008.02.004
  • Ghali J., Murugasu A., Day T., Nicholls K. Carpal tunnel syndrome in Fabry disease. JIMD Rep. 2012; 2:17–23. https://doi.org/10.1007/8904_2011_37
  • Ortiz A, Germain GP, Desnick RJ, Politei J ., Mauer М., Burlina А., Eng С., Hopkin R., Laney D, Linhart A., 10, Waldek S., Wallace E., Weidemann F., William R. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet. Metab. 2018; 123(4):416-27. https://doi.org/10.1016/j.ymgme.2018.02.014